Reardon Andrew

CLO & SecretaryLIGAND PHARMACEUTICALS INC (LGND) · full profile →Form 4 · filed Apr 2, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$1.0M
Net Open-Market Flow
-$1.0M
Transactions
8
7 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Apr 1, 2026Option exercise(M)5K$52.27$261K46K
Apr 1, 2026Sell(S)460$198.85$91K46K
Apr 1, 2026Sell(S)1K$199.72$260K45K
Apr 1, 2026Sell(S)1K$200.94$249K43K
Apr 1, 2026Sell(S)700$201.90$141K43K
Apr 1, 2026Sell(S)963$203.22$196K42K
Apr 1, 2026Sell(S)337$204.50$69K41K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Apr 1, 2026Option exercise(M)5K$049K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0002001011-26-000037) within minutes of acceptance. Every field above traces to the original document. Verify it directly: